Somatropin polysialic - Xenetic Biosciences/SynBio

Drug Profile

Somatropin polysialic - Xenetic Biosciences/SynBio

Alternative Names: Polysialic somatropin; SYN-20100504RU

Latest Information Update: 16 Jun 2014

Price : $50

At a glance

  • Originator Xenetic Biosciences
  • Developer SynBio; Xenetic Biosciences
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Somatotropin deficiency

Most Recent Events

  • 30 Apr 2014 Investigation in Somatotropin deficiency in Russia (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top